As of Jan 17, 2025, Gilead Sciences, Inc. Intrinsic Value is $104.6. This suggests it may be undervalued by 13.9% compared to its current price of around $91.8.
As of Jan 17, 2025, Gilead Sciences, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $118.9. This suggests it may be overvalued by 29.5% to its current price of around $91.8, using a discount rate of 6.7% and terminal growth rate of 3.0%.
Gilead Sciences, Inc. is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $104.6, compared to a market price of around $91.8. This suggests a potential undervaluation of 13.9%.